Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03225183 · ClinicalTrials.gov registry record
RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 1,700
- Enrollment target
NCT03225183: Completed study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT03225183 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,700 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03225183 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 1,700 participants
- Enrollment target
Study Summary
Background: The Framingham Heart Study (FHS) was initiated by the U.S Public Health Service in 1948 and turned over to the newly established National Heart Institute in 1951. The FHS is now jointly led by the National Heart, Lung, and Blood Institute and Boston University. The FHS currently studies risk factors, and the genetics of heart and blood vessel disease, and other health conditions in three generations of study participants. Scientists want to use the data collected from this study to do more research. They want to use a technique that determines the sequence of ribonucleic acid (RNA) molecules. Objective: To study genes related to certain diseases and health conditions. These include heart and blood vessel diseases, lung and blood diseases, stroke, memory loss, and cancer. Eligibility: People in the FHS Third Generation cohort who already attended exam 2. Design: Researchers will study samples that have already been collected in the FHS. There will be no active examination or burden to participants. During FHS visits, participants gave blood samples. They gave permission for the blood to be used for genetic research. RNA will be generated from the samples. They will be given a new ID separate from any personal data. They will be stored in a secure FHS lab. The samples will be analyzed. Only certified researchers can access them. No study participants will be contacted in relation to this project. ...
Primary Outcome
Will look at CVD events related to RNA sequence. a. Characterize the relation of protein-coding gene expression to CVD and its risk factors; b. Characterize the relations of lncRNAs to CVD and risk factors; c. Characterize the relations of RNA splicing variation to CVD and its risk factors; d. Characterize the relations of allele-specific expression, and parent-oforigin allele specific expression, to CVD and its risk factors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,700 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2019-06-17 |
What the finished NCT03225183 record still lists
NCT03225183 is an observational study that tracks outcomes without assigning an intervention. Its 1,700 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03225183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03225183 about?
NCT03225183 is a clinical study titled "RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2". Background: The Framingham Heart Study (FHS) was initiated by the U.S Public Health Service in 1948 and turned over to the newly established National Heart Institute in 1951. The FHS is now jointly led by the National Heart, Lung, and Blood Institute and Boston University. The FHS currently studies...
What is the current status of trial NCT03225183?
This trial is currently completed. The enrollment target is 1,700 participants. The study started on 2017-07-14. Estimated completion is 2019-06-17.
Who is sponsoring clinical trial NCT03225183?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI